ESSA Pharma Inc. (EPIX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.66+0.01 (+0.38%)
At close: 10:20 AM EDT
People also watch:
EMISCNCTENZNARQLINSM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close2.65
Bid2.61 x 400
Ask3.85 x 100
Day's Range2.65 - 2.66
52wk Range2.25 - 7.00
1y Target EstN/A
Market Cap77.4M
P/E Ratio (ttm)-8.81
BetaN/A
Volume970
Avg Vol (3m)3,581
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire13 days ago

    ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016

    HOUSTON, TX and VANCOUVER, Aug. 12, 2016 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX: EPI, NASDAQ: EPIX) today reported financial results for the third quarter and three months ended June 30, 2016.  Amounts, unless specified otherwise, are expressed in United States dollars and in accordance with International Financial Reporting Standards ("IFRS"). ESSA recorded a net loss of $3.9 million ($0.13 per common share) for the three months ended June 30, 2016, compared to a net loss of $4.9 million ($0.29 per common share) for the three months ended June 30, 2015. Research and Development ("R&D") expenditures for the three month period were $3.4 million compared to $2.6 million for 2015.  R&D expenditures in the period are primarily related to manufacturing and clinical costs as the Company continues its work in the clinical development stage with respect to clinical candidate EPI-506.

  • CNW Group13 days ago

    ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016

    ESSA Pharma Inc. reports financial results for the third quarter June 30, 2016

  • PR Newswire24 days ago

    ESSA Names Peter Virsik as Executive Vice President & Chief Operating Officer

    Mr. Virsik will be responsible for leading ESSA's overall business development and corporate strategy as the Company further advances its clinical development plan for the novel prostate cancer therapeutic EPI-506.